

Invitae to acquire ArcherDX for \$1.4 billion

June 30, 2020—[Invitae](#) and [ArcherDX](#) have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company.

The combined company will integrate germline testing, tumor profiling, and liquid biopsy technologies and services in a single platform to enable precision approaches from diagnostic testing to therapy optimization and monitoring, expanding access to personalized oncology.

“Invitae...has strong relationships with clinicians caring for cancer patients, including cancer genetic counselors, oncologists, and imaging centers,” according to a combined press statement. ArcherDX’s platform, with the proprietary Anchored Multiplex PCR chemistry at the core, has enabled the company to develop products and services under investigation to optimize therapy and enable cancer monitoring across liquid and tissue samples. ArcherDX is also currently developing in vitro products, including Stratafide DX for therapy optimization and Personalized Cancer Monitoring for disease recurrence monitoring, therapy optimization including selection, response, and modulation. Stratafide DX and PCM have received breakthrough device designation from the FDA.

The transaction is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX.